GSPT1 Oral MGD

GSPT1 Oral MGD is an orally bioavailable small molecule molecular glue degrader developed by Almac Discovery. It is designed to induce the targeted degradation of G1 to S phase transition protein 1 (GSPT1), a translation termination factor also known as eRF3a. GSPT1 is essential for protein synthesis and is frequently overexpressed in cancers driven by the MYC oncogene, such as acute myeloid leukemia (AML) and certain solid tumors. By acting as a molecular glue, the drug facilitates the recruitment of an E3 ubiquitin ligase to GSPT1, leading to its ubiquitination and subsequent proteasomal degradation. This depletion of GSPT1 triggers translational stress and apoptosis in cancer cells. The program is currently in preclinical development for the treatment of hematologic malignancies, including AML and myelodysplastic syndromes (MDS), as well as MYC-driven solid tumors.

Other names

Almac GSPT1 molecular glue degraderGSPT1 molecular glue degraderGSPT-1 molecular glue degraderGSPT 1 molecular glue degrader